RenBio
Latest round
- Series A
Last raised
- May 2021
Total raised
- $24M
Investors
- 1
About RenBio
, based in the US, specializes in the development of next-generation DNA Therapeutics.RenBio, Inc. was founded in 2016 and is headquartered in New York, US. It operates within the biotechnology sector, focusing on advanced therapeutic solutions.00 mn in a GRANT from the Defense Advanced Research Projects Agency.RenBio DNA Therapeutics specializes in next-generation medicinal products, primarily through its proprietary Make Your Own (MYO) Technology. This innovative platform focuses on delivering therapeutic-encoding 'bioblueprints' via modified intramuscular injections, allowing muscle cells to produce disease-fighting therapeutics within the patient's body. The company aims to modernize the administration of antibody and therapeutic protein treatments to enhance efficacy, durability, and cost-effectiveness, addressing significant barriers in the current healthcare landscape. RenBio’s products target a range of conditions, particularly infectious diseases, by focusing on delivering antiviral antibodies and improving therapeutic protein dosing regimens.RenBio generates revenue through its innovative therapeutic solutions, which are primarily offered via partnerships with healthcare providers and research institutions. These transactions typically involve agreements wherein clients engage with RenBio to access their MYO Technology and associated therapeutic blueprints. The pricing structure for their offerings is based on the complexity and scope of the services provided, potentially involving subscription models for ongoing access to the technology or one-time fees for specific therapies. RenBio’s flagship MYO Technology plays a crucial role in its revenue model, as it represents their core service that enables the production of customized therapeutics directly in patients.00 mn, obtained in October 2022, to further develop its MYO Technology and expand its product offerings. The company is actively designing new therapeutic solutions aimed at infectious diseases, seeking to launch several new products in the coming years. In addition, RenBio is targeting expansion into international markets where there is a significant need for its advanced therapeutic solutions, with plans to establish partnerships in Europe and Asia by 2025.
Who invested in RenBio
1 investor across 1 round
See all investors in RenBio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
May 20, 2021
Amount
$24M
Investors
Questions about RenBio
Who invested in RenBio?
RenBio has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has RenBio raised?
RenBio has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did RenBio last raise money?
RenBio's most recent round on record is a Series A, in May 2021.
What does RenBio do?
, based in the US, specializes in the development of next-generation DNA Therapeutics.
Where is RenBio headquartered?
RenBio is headquartered in New York, US.
Which VCs invest in companies like RenBio?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at RenBio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like RenBio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.